XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Arrangements and Licensing Agreements, Novartis (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Aug. 04, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue   $ 125,750 $ 145,537 $ 237,357 $ 278,905
Novartis [Member] | Maximum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Cumulative payments received   $ 400,000   $ 400,000  
Novartis [Member] | Maximum [Member] | Plan [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next prospective milestone $ 75,000        
Novartis [Member] | Pelacarsen [Member] | Subsequent Event [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 25,000        
Percentage enrollment in Phase 3 study 50.00%